EBS
Income statement / Annual
Last year (2023), Emergent BioSolutions Inc.'s total revenue was $1.05 B,
a decrease of 6.39% from the previous year.
In 2023, Emergent BioSolutions Inc.'s net income was -$760.50 M.
See Emergent BioSolutions Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$1.05 B
|
$1.12 B
|
$1.79 B
|
$1.56 B
|
$1.11 B
|
$782.40 M
|
$560.87 M
|
$488.78 M
|
$522.79 M
|
$450.14 M
|
| Cost of Revenue |
$705.40 M |
$693.70 M |
$757.50 M |
$524.00 M |
$433.50 M |
$322.30 M |
$195.71 M |
$131.28 M |
$124.30 M |
$118.41 M |
| Gross Profit |
$343.90 M |
$427.20 M |
$1.04 B |
$1.03 B |
$672.50 M |
$460.10 M |
$365.17 M |
$357.50 M |
$398.49 M |
$331.73 M |
| Gross Profit Ratio |
0.33 |
0.38 |
0.58 |
0.66 |
0.61 |
0.59 |
0.65 |
0.73 |
0.76 |
0.74 |
| Research and Development
Expenses |
$111.40 M
|
$193.00 M
|
$234.00 M
|
$234.50 M
|
$226.20 M
|
$142.80 M
|
$97.38 M
|
$108.29 M
|
$154.00 M
|
$150.83 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$202.50 M
|
$143.50 M
|
$143.69 M
|
$148.46 M
|
$122.84 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$368.40 M
|
$340.30 M
|
$348.40 M
|
$303.30 M
|
$273.50 M
|
$202.50 M
|
$143.50 M
|
$143.69 M
|
$148.46 M
|
$122.84 M
|
| Other Expenses |
$564.20 M |
$59.90 M |
$58.50 M |
$59.80 M |
$58.70 M |
$1.60 M |
-$815,000.00 |
$263,000.00 |
-$319,000.00 |
$2.93 M |
| Operating Expenses |
$1.04 B |
$593.20 M |
$640.90 M |
$597.60 M |
$558.40 M |
$370.30 M |
$240.88 M |
$251.98 M |
$302.46 M |
$273.67 M |
| Cost And Expenses |
$1.78 B |
$1.29 B |
$1.40 B |
$1.12 B |
$991.90 M |
$692.60 M |
$436.59 M |
$383.26 M |
$426.75 M |
$392.08 M |
| Interest Income |
$0.00 |
$37.30 M |
$34.50 M |
$31.30 M |
$38.40 M |
$0.00 |
$1.75 M |
$1.05 M |
$572,000.00 |
$320,000.00 |
| Interest Expense |
$87.90 M |
$37.30 M |
$34.50 M |
$31.30 M |
$38.40 M |
$9.90 M |
$6.59 M |
$7.62 M |
$6.52 M |
$8.24 M |
| Depreciation &
Amortization |
$125.10 M
|
$148.90 M
|
$126.30 M
|
$114.40 M
|
$110.90 M
|
$61.30 M
|
$40.80 M
|
$38.23 M
|
$35.34 M
|
$32.45 M
|
| EBITDA |
-$505.30 M
|
-$32.90 M
|
$458.20 M
|
$549.00 M
|
$227.30 M
|
$152.70 M
|
$158.13 M
|
$145.07 M
|
$177.57 M
|
$93.76 M
|
| EBITDA Ratio |
-0.48 |
-0.03 |
0.29 |
0.36 |
0.2 |
0.15 |
0.22 |
0.22 |
0.25 |
0.21 |
| Operating Income Ratio
|
-0.69
|
-0.15
|
0.2
|
0.28
|
0.1
|
0.11
|
0.22
|
0.22
|
0.18
|
0.13
|
| Total Other
Income/Expenses Net |
-$4.80 M
|
-$53.00 M
|
-$38.20 M
|
-$26.60 M
|
-$36.70 M
|
-$8.30 M
|
-$5.70 M
|
-$6.30 M
|
-$5.80 M
|
-$4.99 M
|
| Income Before Tax |
-$731.20 M |
-$221.70 M |
$314.40 M |
$407.20 M |
$77.40 M |
$81.50 M |
$118.63 M |
$99.22 M |
$89.77 M |
$53.06 M |
| Income Before Tax Ratio
|
-0.7
|
-0.2
|
0.18
|
0.26
|
0.07
|
0.1
|
0.21
|
0.2
|
0.17
|
0.12
|
| Income Tax Expense |
$29.30 M |
$2.10 M |
$83.50 M |
$102.10 M |
$22.90 M |
$18.80 M |
$36.04 M |
$36.70 M |
$26.90 M |
$16.32 M |
| Net Income |
-$760.50 M |
-$223.80 M |
$219.50 M |
$305.80 M |
$54.50 M |
$62.70 M |
$82.59 M |
$51.78 M |
$62.87 M |
$36.74 M |
| Net Income Ratio |
-0.72 |
-0.2 |
0.12 |
0.2 |
0.05 |
0.08 |
0.15 |
0.11 |
0.12 |
0.08 |
| EPS |
-14.85 |
-4.47 |
4.1 |
5.79 |
1.06 |
1.25 |
1.98 |
1.29 |
1.63 |
0.98 |
| EPS Diluted |
-14.85 |
-4.47 |
4.06 |
5.67 |
1.04 |
1.22 |
1.71 |
1.13 |
1.41 |
0.88 |
| Weighted Average Shares
Out |
$51.20 M
|
$50.10 M
|
$53.50 M
|
$52.70 M
|
$51.50 M
|
$50.10 M
|
$41.82 M
|
$40.18 M
|
$38.60 M
|
$37.34 M
|
| Weighted Average Shares
Out Diluted |
$51.20 M
|
$50.10 M
|
$54.10 M
|
$53.80 M
|
$52.40 M
|
$51.40 M
|
$50.33 M
|
$49.34 M
|
$47.26 M
|
$45.80 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
